Andrea Sorrentino's practice focuses on all aspects of corporate law. She represents public and private companies in a variety of industries, including technology, life sciences and financial services. Ms. Sorrentino has represented clients on a wide range of complex capital markets and financing transactions, including venture financings, initial public offerings, private placements, and follow-on equity offerings. She also regularly advises clients on ongoing disclosure requirements, SEC reporting and corporate governance matters.

Experience

  • Capital Markets

    • Schrödinger in its initial public offering and subsequent follow-on public offering of approximately $579 million
    • Inozyme Pharma in its $128.8 million initial public offering, $73.1 million follow-on offering and $69 million follow-on offering
    • Fulcrum Therapeutics in its $72 million initial public offering, $68.5 million private placement, $50.6 million follow-on offering and $144.2 million follow-on offering
    • Cue Health in its $200 million initial public offering
    • Nuvalent in its $281.6 million follow-on public offering 
    • Solid Biosciences in its $200 million follow-on public offering
    • Verve Therapeutics in its $225 million follow-on public offering and in its $125 million follow-on public offering
    • Ocular Therapeutix, Inc. in its $115 million follow-on public offering and its $325 million private placement
    • Curis in its $15.1 million registered direct offering
    • Astria Therapeutics in its $125 million underwritten registered direct offering
    • Xilio Therapeutics in its $50 million offering
    • Underwriters in Viridian’s $254 million follow-on public offering
    • Casella Waste Systems in its $517.5 million follow-on public offering 
    • KALA BIO in its $134 million public offering and $10.75 million private placement
    • Numerous ATM offerings for clients
  • Venture Capital

    • Schrödinger in its $110 million Series E financing 
    • Ribon Therapeutics in its $65 million Series B financing
    • Inozyme Pharma in its $67 million Series A-2 financing
    • Fulcrum Therapeutics in its $80 million Series B financing
    • Pandion Therapeutics in its $58 million Series A financing
    • Sonde Health in its $19.25 million Series B financing 
    • Tvardi Therapeutics in its $9 million Series A financing
    • Immuta in its $100 million Series E financing and in its $90M Series D financing

Recognition

  • Selected for inclusion in Best Lawyers: Ones to Watch for corporate law (2023–2025) and corporate governance and compliance law (2024–2025)
  • Named to Boston Magazine’s inaugural Top Lawyers list in 2021 and 2022 in the area of corporate law

Insights & News

Credentials

  • Education

    • JD, Boston University School of Law, 2015

      magna cum laude

      Editor, Boston University Law Review, Edward F. Hennessey Distinguished Scholar

    • BA, Political Science, Boston University, 2011

      summa cum laude

  • Admissions

    • New York

    • Massachusetts

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.